Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

Fig. 1

Kinetics of anti-S-RBD IgGs development in convalescent versus naïve (part of data for naïve donors have been reported in [20]) recipients of the BNT162b2 mRNA vaccine. Anti-S-RBD IgG antibodies in shown individuals at D1 (first dose of the vaccine), D8, D22 (second vaccination), D36, and D50. POS, convalescent recipients (P1) being also positive for NAbs (see Fig. 2); NEG, naïve recipients (shown n values denote the number of enrolled individuals per category). Median age of donors, number of males (M)/females (F), mean, standard deviation (SD) and median values of U/mL for this assay at D1–D50 are also shown. Blue/red arrows indicate 2/10 POS individuals with relatively low anti-S-RBD IgG titers at D1 and D8

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us